Adeno-associated virus (AAV) is the leading vector in emerging treatments of inherited
diseases. Higher transduction efficiencies and cellular specificity are required for broader …

Over the past 5 years, our laboratory has systematically developed a structure-guided library
approach to evolve new adeno-associated virus (AAV) capsids with altered tissue tropism …

Adeno-associated virus (AAV) is a highly promising gene transfer vector, yet major cellular
requirements for AAV entry are poorly understood. Using a genome-wide CRISPR screen …

The blood-brain barrier (BBB) presents a major challenge for delivering large molecules to
study and treat the central nervous system. This is due in part to the scarcity of targets known …

The presence of the blood-brain barrier (BBB) remains a challenge in the treatment of
central nervous system (CNS) diseases, as it hinders the infiltration of many therapeutic …

As adeno-associated virus (AAV)-based gene therapies are being increasingly approved for
use in humans, it is important that we understand vector–host interactions in detail. With the …

Central nervous system (CNS) diseases are some of the most difficult to treat because the
blood-brain barrier (BBB) almost entirely limits the passage of many therapeutic drugs into …

Adeno-associated virus (AAV) has a single-stranded DNA genome encapsidated in a small
icosahedrally symmetric protein shell with 60 subunits. AAV is the leading delivery vector in …

Human gene therapy has advanced from twentieth-century conception to twenty-first-century
reality. The recombinant Adeno-Associated Virus (rAAV) is a major gene therapy vector …

Over 100 human adenoviruses (HAdVs) have been isolated and allocated to seven species,
AG. Species F comprises two members-HAdV-F40 and HAdV-F41. As their primary site of …